Clinical Research Directory

Inclusion Criteria: 1. Age: 18 to 80 years old (inclusive) 2. Diagnosis: Confirmed type 1 or type 2 diabetes mellitus 3. Meeting diagnostic criteria for diabetic lower extremity arterial disease (DLEAD) 4. TCM Syndrome: Qualified for Qi Stagnation and Blood Stasis syndrome pattern 5. Glycemic Control: * HbA1c ≤9% or Fasting plasma glucose ≤10 mmol/L 6. Ulcer History: * Documented history of diabetic lower extremity arterial disease (DLEAD)-related ulcers, with confirmed healing (wound re-epithelialization without signs of redness, purulent discharge, or infection) 2-8 weeks prior to enrollment. 7. Consent: Voluntarily signed informed consent form Exclusion Criteria: * (1) Ulcer Etiology Exclusion: * Pure pressure ulcers * Pure neuropathic ulcers * Immune-mediated ulcers (e.g., vasculitic ulcers caused by lupus, Behcet's disease, rheumatoid arthritis) (2) Recent Cardiovascular Events: * Acute coronary syndrome within 3 months * Hemorrhagic stroke within 3 months (3) Organ Dysfunction: * Severe hepatic impairment (AST or ALT \>1.5×ULN) * Chronic kidney disease stage 4-5 (eGFR \<30 mL/min/1.73m²) (4) Recent Major Bleeding: * Gastrointestinal hemorrhage within 1 month (5) Concurrent TCM Therapy: * Use of blood-activating/stasis-resolving TCM preparations for DLEAD within 1 week (6) Herbal Contraindication: * Concurrent or planned use of \*Veratrum\*-containing preparations (7) Malignancy: * Active cancer progression (8) Reproductive Status: * Pregnant or lactating women (9) Allergy History: * Known hypersensitivity to \*Ligusticum chuanxiong\* or \*Salvia miltiorrhiza\* (10) Cognitive/Language Barriers: * Psychiatric disorders * Intellectual/language impairment affecting scale completion * Unwillingness to cooperate (11) Life Expectancy: * \<1 year (12) Clinical Trial Participation: * Enrollment in other drug trials within 1 month (13) Investigator's Discretion: * Other conditions deemed unsuitable for participation